Prof. Dr. Dr. Carole Bourquin

Diploma and degrees

• 1995
  Diploma of Medicine, University of Geneva, Switzerland
  
  

• 1996
  Doctorate in Medicine, University of Geneva, Switzerland
  
  

• 2000
  Doctorate in Biology, Ludwig-Maximilian University of Munich, Germany
  
  

• 2008
  Specialist for Clinical Pharmacology
  
  

• 2009
  Specialist for Immunology
  
  

Postgraduate Education

• 2000 – 2001
  Postdoctoral fellow, Max-Planck Institute for Neurobiology, Division of Neuroimmunology, Munich (Germany)
  
  

• 2002 – 2003
  Postdoctoral fellow, Clinic of Medicine, Hematology-Oncology, Ludwig-Maximilian University Hospital of Munich (Germany)
  
  

Clinical appointments

• 1995
  Resident (Médecin assistant), Clinic of Medicine I, University Hospital of Geneva, Geneva, Switzerland
  
  

• 2003 – 2005
  Resident (Assistenzärztin)
  
  

• 2003 – 2011
  Physician, Division of Clinical Pharmacology, Ludwig-Maximilian University Hospital of Munich
  
  

• 2006 – 2011
  Senior Physician (Oberärztin)
  
  

• since 2012
  Clinical Pharmacologist, Fribourg Regional Hospital, President of the Hospital Drug Commission
  
  

Academic appointments

• 2004 – 2011
  Head of the research group Tumor Immunology, Division of Clinical Pharmacology, Ludwig-Maximilian University of Munich
  
  

• 2009
  Habilitation in Clinical Pharmacology, Ludwig-Maximilian University of Munich
  
  

• since 2011
  Professor and Chair of Pharmacology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
  
  

• Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. Journal of the National Cancer Institute 2014 Nov 24;107. (Journal impact factor, JIF 15.2)

• Roehnisch T, Then C, Nagel W, Blumenthal C, Braciak T, Donzeau M, Böhm T, Flaig M, Bourquin C*, Oduncu F* (*shared senior authorship)Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.Journal of Translational Medicine 2014, 12:119 (JIF 3.5)

• Heidegger S, Anz D, Stephan N, Bohn B, Herbst T, Fendler WP, Suhartha N, Sandholzer N, Kobold S, Hotz C, Eisenächer K, Radtke-Schuller S, Endres S, Bourquin C.Virus-associated activation of innate immunity induces rapid disruption of Peyer's patches in mice.Blood 2013, 122:2591-9. (JIF 9.0)

• Heidegger S, Kirchner S, Stephan N, Bohn B, Suhartha N, Hotz C, Anz D, Sandholzer N, Stecher B, Rüssmann H, Endres S, Bourquin C.TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in mice.Journal of Immunology 2013, 190:5313-20 (JIF 5.6)

• Schüller VJ, Heidegger S, Sandholzer N, Nickels PC, Suhartha NA, Endres S, Bourquin C*, Liedl T* (*shared senior authorship)Cellular Immunostimulation by CpG-Sequence-Coated DNA Origami Structures. ACS Nano 2011, 5:9696-702 (JIF 9.9)

• Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, Endres S (2011). Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Research, 71:5123-33 (JIF 7.5) Authors’ View in: Oncoimmunology 2011, 1: 227-228

• Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.Clinical Cancer Research 2011, 17:1765-75 (JIF 6,7)Comment in: Clinical Cancer Research 2011, 17:1765-75 (2012)

• Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann W, Endres S. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in a SV40 T antigen mouse model. Journal of Immunology 2010; 185:2580-8 (JIF 5,6)

• Anz D, Koelzer VH, Moder S, Thaler R, Schwerdt T, Lahl K, Sparwasser T, Besch R, Poeck H, Hornung V, Rothenfusser S, Bourquin C*, Endres S. (* corresponding author)Blockade of regulatory T cell suppression by Toll-like receptor 7-activating immunostimulatory RNA oligonucleotides.Journal of Immunology 2010; 184:939-46 (JIF 6,1)

• Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, Berger M, Poeck H, Hartmann G, Hornung V, Endres S.Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK-cell response through the Toll-like receptor 7.Journal of Immunology 2009; 183:6078-86 (JIF 6,1)

• Journal impact factors (JIF) are given for the year of publication

Reviewer activities for grant foundations and scientific journals:

• Grant foundations: Oncosuisse (Swiss Cancer Foundation), German Cancer Foundation, BONFOR-Program of the University of Bonn

• Scientific journals: Cancer Research, International Journal of Cancer, European Journal of Cancer, Cancer Immunology and Immunotherapy, Neoplasia, Journal of Translational Medicine, Journal of Immunology, Journal of Leukocyte Biology, Vaccine, Molecular Pharmaceutics, Allergy, Journal of Visualized Experiments, Chemical Science

You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here